{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:33:41Z","timestamp":1789616021003,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ejmech.2022.114215","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T21:51:11Z","timestamp":1645566671000},"page":"114215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Synthesis, bioevaluation and molecular dynamics of pyrrolo-pyridine benzamide derivatives as potential antitumor agents in\u00a0vitro and in\u00a0vivo"],"prefix":"10.1016","volume":"233","author":[{"given":"Jianqing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintian","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qidong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114215_bib1","doi-asserted-by":"crossref","first-page":"103970","DOI":"10.1016\/j.bioorg.2020.103970","article-title":"Discovery of novel dual c-Met\/HDAC inhibitors as a promising strategy for cancer therapy","volume":"101","author":"Hu","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2022.114215_bib2","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114215_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-397918-6.00001-X","article-title":"Catalytic mechanisms and regulation of protein kinases","volume":"548","author":"Wang","year":"2014","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.ejmech.2022.114215_bib4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrc2787","article-title":"Targeting the cancer kinome through polypharmacology","volume":"10","author":"Knight","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2022.114215_bib5","doi-asserted-by":"crossref","first-page":"105463","DOI":"10.1016\/j.phrs.2021.105463","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2022.114215_bib6","doi-asserted-by":"crossref","first-page":"112643","DOI":"10.1016\/j.ejmech.2020.112643","article-title":"Identification of novel quinoline analogues bearing thiazolidinones as potent kinase inhibitors for the treatment of colorectal cancer","volume":"204","author":"Zhou","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114215_bib7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","article-title":"Mechanisms of receptor tyrosine kinase activation in cancer","volume":"17","author":"Du","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2022.114215_bib8","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114215_bib9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40264-018-0780-x","article-title":"Safety and tolerability of c-MET inhibitors in cancer","volume":"42","author":"Puccini","year":"2019","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejmech.2022.114215_bib10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2741\/4114","article-title":"Biological significance and targeting of c-Met tyrosine kinase receptor in cancer","volume":"18","author":"Goetsch","year":"2013","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ejmech.2022.114215_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12943-018-0796-y","article-title":"Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2022.114215_bib12","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1242\/jcs.191684","article-title":"Acid sphingomyelinase is required for cell surface presentation of Met receptor tyrosine kinase in cancer cells","volume":"129","author":"Zhu","year":"2016","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.ejmech.2022.114215_bib13","doi-asserted-by":"crossref","first-page":"37370","DOI":"10.18632\/oncotarget.8276","article-title":"Biomarker development in MET-targeted therapy","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2022.114215_bib14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1023\/A:1023768811842","article-title":"Structure, functions and potential for therapeutic inhibition","volume":"22","author":"Ma","year":"2003","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejmech.2022.114215_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2004.09.044","article-title":"c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention","volume":"225","author":"Christensen","year":"2005","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2022.114215_bib16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3390\/cancers10090280","article-title":"Status of agents targeting the HGF\/c-Met Axis in lung cancer","volume":"10","author":"Miranda","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2022.114215_bib17","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/cas.13092","article-title":"Functional and therapeutic relevance of hepatocyte growth factor\/c-MET signaling in synovial sarcoma","volume":"107","author":"Imura","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2022.114215_bib18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.canlet.2015.05.028","article-title":"c-Met targeting in advanced gastric cancer: an open challenge","volume":"365","author":"Marano","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2022.114215_bib19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/13543784.2020.1699532","article-title":"MET inhibitors in cancer: pitfalls and challenges","volume":"29","author":"Oliveres","year":"2020","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2022.114215_bib20","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nrd2530","article-title":"Drug development of MET inhibitors: targeting oncogene addiction and expedience","volume":"7","author":"Comoglio","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114215_bib21","doi-asserted-by":"crossref","first-page":"104356","DOI":"10.1016\/j.bioorg.2020.104356","article-title":"Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors","volume":"104","author":"Luo","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2022.114215_bib22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40264-018-0780-x","article-title":"Safety and tolerability of c-MET inhibitors in cancer","volume":"42","author":"Puccini","year":"2019","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejmech.2022.114215_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/17460441.2019.1551355","article-title":"Optimization techniques for novel c-Met kinase inhibitors","volume":"14","author":"Sun","year":"2019","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114215_bib24","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1016\/j.bmc.2017.04.003","article-title":"Synthesis and evaluation of a series of pyridine and pyrimidine derivatives as type II c-Met inhibitors","volume":"25","author":"Zhao","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114215_bib25","doi-asserted-by":"crossref","first-page":"112244","DOI":"10.1016\/j.ejmech.2020.112244","article-title":"Design, synthesis and biological evaluation of novel N-[4-(2-fluorophenoxy)pyridin-2-yl]cyclopropanecarboxamide derivatives as potential c-Met kinase inhibitors","volume":"194","author":"Liu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114215_bib26","doi-asserted-by":"crossref","first-page":"112241","DOI":"10.1016\/j.ejmech.2020.112241","article-title":"Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions","volume":"193","author":"Nan","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114215_bib27","doi-asserted-by":"crossref","first-page":"6836","DOI":"10.1016\/j.bmcl.2009.10.095","article-title":"N3-arylmalonamides: a new series of thieno[3,2-b]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases, Bioorg","volume":"19","author":"Saavedra","year":"2009","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114215_bib28","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1021\/jm800476q","article-title":"Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities","volume":"51","author":"Kim","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114215_bib29","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1021\/jm801586s","article-title":"Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily","volume":"52","author":"Schroeder","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114215_bib30","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1016\/j.bmc.2017.06.037","article-title":"Design, synthesis and biological evaluation of novel 4-phenoxyquinoline derivatives containing 3-oxo-3,4-dihydroquinoxaline moiety as c-Met kinase inhibitors","volume":"25","author":"Liu","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114215_bib31","doi-asserted-by":"crossref","first-page":"112651","DOI":"10.1016\/j.ejmech.2020.112651","article-title":"Discovery of Novel c-Mesenchymal-Epithelia transition factor and histone deacetylase dual inhibitors","volume":"204","author":"Hu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114215_bib32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2144\/btn-2020-0057","article-title":"PCR past, present and future","volume":"69","author":"Zhu","year":"2020","journal-title":"Biotechniques"},{"key":"10.1016\/j.ejmech.2022.114215_bib33","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/jcmm.13923","article-title":"Rapid detection of low-level HeLa cell contamination in cell culture using nested PCR","volume":"23","author":"Lin","year":"2019","journal-title":"J.\u00a0Cell Mol. Med."},{"key":"10.1016\/j.ejmech.2022.114215_bib34","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1021\/acs.jcim.6b00551","article-title":"Discovery of novel phosphodiesterase-2A inhibitors by structure-based virtual screening structural optimization, and bioassay","volume":"57","author":"Zhang","year":"2017","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2022.114215_bib35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejmech.2016.03.033","article-title":"Design, synthesis, biological evaluation and docking studies of novel 2-substituted-4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as dual PI3K\u03b1\/mTOR inhibitors","volume":"116","author":"Lei","year":"2016","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422001179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422001179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:38:11Z","timestamp":1759329491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422001179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":35,"alternative-id":["S0223523422001179"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114215","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis, bioevaluation and molecular dynamics of pyrrolo-pyridine benzamide derivatives as potential antitumor agents in\u00a0vitro and in\u00a0vivo","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114215","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114215"}}